342 related articles for article (PubMed ID: 33317398)
21. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
[TBL] [Abstract][Full Text] [Related]
22. Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer.
Trakunram K; Chaniad P; Geater SL; Keeratichananont W; Chittithavorn V; Uttayamakul S; Buya S; Raungrut P; Thongsuksai P
Cancer Biol Med; 2020 Aug; 17(3):652-663. PubMed ID: 32944397
[No Abstract] [Full Text] [Related]
23. A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.
Zhou C; Chen Z; Zhao L; Zhao W; Zhu Y; Liu J; Zhao X
J Clin Lab Anal; 2020 Nov; 34(11):e23505. PubMed ID: 33463758
[TBL] [Abstract][Full Text] [Related]
24. Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients.
Zhang Y; Zhang Y; Yin Y; Li S
Pathol Res Pract; 2019 Aug; 215(8):152466. PubMed ID: 31146974
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion.
Han HS; Yun J; Lim SN; Han JH; Lee KH; Kim ST; Kang MH; Son SM; Lee YM; Choi SY; Yun SJ; Kim WJ; Lee OJ
Int J Cancer; 2013 Aug; 133(3):645-52. PubMed ID: 23354517
[TBL] [Abstract][Full Text] [Related]
26. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients].
Duan X; Cui Y; Gong M; Tian F; Shi G; Wu B; Liu M; Guo J; Kong Y
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):358-64. PubMed ID: 26104892
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
28. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer.
Wang L; Wang D; Zheng G; Yang Y; Du L; Dong Z; Zhang X; Wang C
Int J Biol Markers; 2016 Feb; 31(1):e80-7. PubMed ID: 26560853
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.
Su K; Zhang T; Wang Y; Hao G
World J Surg Oncol; 2016 Aug; 14(1):224. PubMed ID: 27733164
[TBL] [Abstract][Full Text] [Related]
30. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer.
Sun M; Song J; Zhou Z; Zhu R; Jin H; Ji Y; Lu Q; Ju H
Dis Markers; 2016; 2016():3823121. PubMed ID: 26880855
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer.
Zhang ZH; Han YW; Liang H; Wang LM
Cancer Med; 2015 Nov; 4(11):1633-8. PubMed ID: 26333429
[TBL] [Abstract][Full Text] [Related]
33. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
[TBL] [Abstract][Full Text] [Related]
34. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
35. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.
Yuxia M; Zhennan T; Wei Z
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2045-50. PubMed ID: 22806310
[TBL] [Abstract][Full Text] [Related]
36. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
[TBL] [Abstract][Full Text] [Related]
37. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
[TBL] [Abstract][Full Text] [Related]
38. Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer.
Soliman SE; Abdelaleem AH; Alhanafy AM; Ibrahem RAL; Elhaded ASA; Assar MFA
Mol Biol Rep; 2021 Mar; 48(3):2543-2552. PubMed ID: 33837901
[TBL] [Abstract][Full Text] [Related]
39. Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis.
Xue WX; Zhang MY; Rui Li ; Liu X; Yin YH; Qu YQ
Biomed Res Int; 2020; 2020():9601876. PubMed ID: 32724822
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of Serum miR-629 Predicts Poor Prognosis for Non-Small-Cell Lung Cancer.
Liu F; Li T; Hu P; Dai L
Dis Markers; 2021; 2021():8819934. PubMed ID: 33763157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
